TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01215149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Study: NCT01749267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal only at enamel dentin junction.
Description: Partial caries removal only at enamel dentin junction (EDJ) without carious dentin removal at the pulpal site and restoration with glass ionomer cement(SMART restoration)
Study: NCT02356627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Cancer Home Life Intervention
Description: Adaptive interventions aiming at compensating for functional limitations.
Study: NCT01215149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer
Study: NCT02107989

Intervention type: DEVICE
Intervention: MRI
Description: MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.

Intervention type: DEVICE
Intervention: MRI
Description: MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.

Intervention type: DEVICE
Intervention: MEG
Description: MEG/EEG: Magnetoencephalography (MEG) is commonly used during epilepsy pre-surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only.

Intervention type: DEVICE
Intervention: MEG
Description: MEG/EEG: Magnetoencephalography (MEG) is commonly used during epilepsy pre-surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only.
Study: NCT03246347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT+Docetaxel+Enzalutamide
Description: combination therapy as listed above
Study: NCT02620852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete a health questionnaire
Description: Complete a health history questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete a health questionnaire
Description: Complete a health history questionnaire.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provide a saliva sample for genetic testing
Description: Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening advice based on a comprehensive risk assessment
Description: Receive a screening schedule recommendation
Study: NCT01215149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer
Study: NCT02620852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening advice based on a basic risk assessment
Description: Receive a screening schedule recommendation
Study: NCT04856735

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraperİtoneal local anaesthesİc İn cesarean sectİon
Description: After the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local wound infiltrasyon
Description: A solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: One of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
Study: NCT01385046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Fit
Description: physical activity and nutrition education
Study: NCT03815058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran
Description: Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran
Description: Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
Study: NCT00398190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard anti-tobacco programming

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Literacy
Description: Anti-smoking media literacy curriculum intervention
Study: NCT02023333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: All patients that meet the eligibility criteria who have signed informed consent and have enrolled on the trial will be treated with regorafenib, daily 3 weeks on 1 week off for all cycles. Dose will be escalated to 120 mg in week 2 of cycle 1 and all remaining cycles if no excess toxicity is experienced by the patient at the discretion of the treating physician.
Study: NCT04198155

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: Image-guided stereotactic body radiation therapy
Study: NCT04091698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-Enzyme Q10 mucoadhesive tablets
Description: will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Co-Enzyme Q10 mucoadhesive tablets
Description: will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
Study: NCT03564340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4018
Description: REGN4018 will be administered in a series of dose escalation and dose expansion cohorts by intravenous (IV) infusion and/or subcutaneous (SC) as described in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4018
Description: REGN4018 will be administered in a series of dose escalation and dose expansion cohorts by intravenous (IV) infusion and/or subcutaneous (SC) as described in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Cemiplimab will be administered by IV infusion after REGN4018 monotherapy lead-in phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Sarilumab will be administered by IV, one-time-only, prior to IV/SC REGN4018.
Study: NCT02155270

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal precut 600µm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal stabincision
Study: NCT02369471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42006

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00919451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclosporin
Description: Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
Study: NCT03554408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Subcutaneous injection of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Subcutaneous injection of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Subcutaneous injection of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Subcutaneous injection of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Subcutaneous injection of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Subcutaneous injection of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Subcutaneous injection of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Intravenous infusion of 10-1074-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Subcutaneous injection of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Subcutaneous injection of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Subcutaneous injection of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Subcutaneous injection of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Subcutaneous injection of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS
Study: NCT02047162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate
Study: NCT01896765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Prevention Program
Description: Study nurse-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical and interventional therapy
Description: Medical and interventional therapy following the standard of care.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard medical and interventional therapy
Description: Medical and interventional therapy following the standard of care.
Study: NCT00663611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin
Description: Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin
Description: Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% normal saline
Study: NCT04115072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel 600Mg Oral Tablet x 5
Description: Five doses of Praziquantel 40 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel 600Mg Oral Tablet x 1
Description: Single dose of Praziquantel 40 mg/kg
Study: NCT03076905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Evaluation of AUC0-t
Study: NCT00258739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine
Description: Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Docetaxel + gemcitabine + carboplatin + radiotherapy
Description: Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).
Study: NCT01215149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Colorless 10mm Tris/HCl buffer
Study: NCT01064362

Intervention type: DRUG
Intervention: Fondaparinux sodium
Description: Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)

Intervention type: DRUG
Intervention: Low molecular weight heparin (LMWH)
Description: LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
Study: NCT01504373

Intervention type: DEVICE
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Description: Subjects will be placed in the NAVA mode of ventilation.

Intervention type: DEVICE
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Description: Subjects will be placed in the NAVA mode of ventilation.
Study: NCT01706432

Intervention type: RADIATION
Intervention: hyperfractionated radiation therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: RADIATION
Intervention: stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery
Study: NCT03086005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Study: NCT03279601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Dacarbazine
Description: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Temozolomide
Description: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
Study: NCT03327857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neihulizumab (ALTB-168)
Description: Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.~Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks.
Study: NCT02805946

Intervention type: DRUG
Group type: OTHER
Intervention: posaconazole
Description: iv versus oral

Intervention type: DRUG
Group type: OTHER
Intervention: posaconazole
Description: iv versus oral
Study: NCT03193229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MapTrek
Description: The objective of the study is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for or already diagnosed with pre-diabetes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Fitbit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit
Study: NCT03655600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-administered acupressure
Description: Self-administered acupressure learned through app for reduction of need for opioids post-surgery in breast cancer patients
Study: NCT01719991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse case management and self-management support
Description: Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.~Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease.
Study: NCT00944632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK 245186
Description: Once daily topical non-occlusive application for up to 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK 245186
Description: Once daily topical non-occlusive application for up to 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK 245186
Description: Once daily topical non-occlusive application for up to 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle ointment)
Description: Once daily topical non-occlusive application for up to 4 weeks
Study: NCT00672633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza , 4 grams/day orally for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn Oil Pill, 4 pills/day orally for 6 months
Study: NCT00778791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin HC1 750 mg extended-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin HC1 750 mg extended-release tablets
Study: NCT01298167

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate tissue glue versus Fast absorbing gut
Description: All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate tissue glue versus Fast absorbing gut
Description: All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.